CureVac · ISIN: NL0015436031 · EQS - Company News

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer   Experienced CFO and investment banker with 30-year track record will help drive CureVac’s transformation  TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Ax...

NASDAQ:CVAC Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News CureVac

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
04 November 2024 01:03PM
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
NL0015436031
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer   Experienced CFO and investment banker with 30-year track record will help drive CureVac’s transformation  TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmac...
CureVac
About the publication
04 November 2024 01:00PM
CureVac to Present at the 12th International mRNA Health Conference
NL0015436031
 CureVac to Present at the 12th International mRNA Health Conference  TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that new and updated data will be share...
CureVac
About the publication
28 October 2024 01:00PM
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
NL0015436031
 CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting   TÜBINGEN, Germany/BOSTON, USA – October 28, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced poster presentati...
CureVac
About the publication
13 September 2024 01:57PM
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
NL0015436031
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress   Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, observed in pa...
CureVac
About the publication
13 September 2024 01:57PM
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
NL0015436031
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress   Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, observed in pa...
CureVac
About the publication
12 September 2024 12:57PM
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
NL0015436031
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program   Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints  Vaccine candidate based on CureVac’s proprietary second-generation mRNA backbone GSK...
CureVac
About the publication
12 September 2024 12:57PM
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
NL0015436031
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program   Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints  Vaccine candidate based on CureVac’s proprietary second-generation mRNA backbone GSK...
CureVac
About the publication
09 September 2024 01:00PM
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
NL0015436031
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress   TÜBINGEN, Germany/BOSTON, USA – September 9, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the f...
CureVac
About the publication
15 August 2024 01:06PM
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
NL0015436031
CureVac Announces Financial Results for the Second Quarter and First Half of 2024and Provides Business Update   Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac’s mRNA platform Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business...
CureVac
About the publication
15 August 2024 01:03PM
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
NL0015436031
 CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma   First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM Part B expected to include up to 20 patients to generate extended data on safety, tolerability, an...
CureVac
About the publication
15 August 2024 01:00PM
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
NL0015436031
 CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board  TÜBINGEN, Germany/BOSTON, USA – August 15, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today named clinical oncologist ...
CureVac
About the publication
11 July 2024 01:00PM
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
NL0015436031
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech   New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by Eu...
CureVac
About the publication
03 July 2024 08:12AM
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
NL0015436031
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities   Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology a...
CureVac
About the publication
03 July 2024 08:09AM
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
NL0015436031
GSK and CureVac to Restructure Collaboration into New Licensing Agreement   GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations   CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales miles...
CureVac
About the publication
24 June 2024 10:05PM
CureVac Announces Voting Results of General Meeting
NL0015436031
CureVac Announces Voting Results of General Meeting   TÜBINGEN, Germany/BOSTON, USA – June 24, 2024 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general mee...
CureVac
About the publication
28 May 2024 01:00PM
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
NL0015436031
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK   Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combi...
CureVac
About the publication
23 May 2024 01:00PM
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
NL0015436031
CureVac Announces Financial Results for the First Quarter of 2024and Provides Business Update   Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate joint...
CureVac
About the publication
23 May 2024 01:00PM
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
NL0015436031
CureVac Announces Financial Results for the First Quarter of 2024and Provides Business Update   Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate joint...
CureVac
About the publication
24 April 2024 01:06PM
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
NL0015436031
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update   Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs   Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, a...
CureVac
About the publication
24 April 2024 01:03PM
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
NL0015436031
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK   Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine ca...
CureVac
About the publication
24 April 2024 01:00PM
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
NL0015436031
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer   Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making   Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN,...
CureVac
About the publication
18 April 2024 01:00PM
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
NL0015436031
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024  TÜBINGEN, Germany/BOSTON, USA – April 18, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financ...
CureVac
About the publication
16 April 2024 01:00PM
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
NL0015436031
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines   Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise   Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematologic...
CureVac
About the publication
04 April 2024 01:00PM
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
NL0015436031
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK   Seasonal flu vaccine candidate boosted antibody titers at all dose levels and for all encoded seasonal influenza strains across younger and older adults Potentially differentiated, multivalent candidate encodes antigen...
CureVac
About the publication
05 January 2024 01:00PM
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
NL0015436031
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform   Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile M...
CureVac
About the publication
19 December 2023 03:23PM
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
NL0015436031
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE   Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by BioNTech SE Decision does not affect ongoing litigation in Germany regarding seven other intellectual property rights, covering stron...
CureVac
About the publication
14 November 2023 01:00PM
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
NL0015436031
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update   Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in seasonal flu Phase 2 study with potentially differentiated mul...
CureVac
About the publication
01 November 2023 01:00PM
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
NL0015436031
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK   COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of combined Phase ...
CureVac
About the publication
28 September 2023 01:00PM
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
NL0015436031
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany   Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTech Ruling on infringement to be provided latest once the validity of the intellectual property rights in suit has b...
CureVac
About the publication
12 September 2023 01:00PM
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
NL0015436031
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage   Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidate   Best-performing candidate providing...
CureVac
About the publication
17 August 2023 01:00PM
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
NL0015436031
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Initiated Phase 1 study of cancer vaccine candida...
CureVac
About the publication
01 August 2023 01:00PM
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
NL0015436031
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK   Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine develo...
CureVac
About the publication
01 August 2023 01:00PM
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
NL0015436031
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK   Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidates Vaccine candidates developed in collaboration with GSK within COVID-19 vaccine develo...
CureVac
About the publication
14 July 2023 01:00PM
CureVac Announces Update to the Management Team
NL0015436031
CureVac Announces Update to the Management Team   TÜBINGEN, Germany / BOSTON, USA – July 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer,...
CureVac
About the publication
14 July 2023 01:00PM
CureVac Announces Update to the Management Team
NL0015436031
CureVac Announces Update to the Management Team   TÜBINGEN, Germany / BOSTON, USA – July 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Dr. Igor Splawski, CureVac’s Chief Scientific Officer,...
CureVac
About the publication
13 July 2023 01:00PM
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
NL0015436031
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights   Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted ...
CureVac
About the publication
13 July 2023 01:00PM
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
NL0015436031
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights   Cases in Germany and the U.S. broadened by asserting additional, new intellectual property rights Three new intellectual property rights added to infringement lawsuit against Pfizer/BioNTech in Germany, increasing number of asserted ...
CureVac
About the publication
20 June 2023 01:05PM
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
NL0015436031
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma   Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma Study designed to evaluate safety and immunogenicity in patients with glioblastoma aft...
CureVac
About the publication
20 June 2023 01:05PM
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
NL0015436031
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma   Cancer vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated antigens with demonstrated relevance in glioblastoma Study designed to evaluate safety and immunogenicity in patients with glioblastoma aft...
CureVac
About the publication
20 June 2023 01:00PM
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
NL0015436031
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board   TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Mich...
CureVac
About the publication
20 June 2023 01:00PM
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
NL0015436031
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board   TÜBINGEN, Germany / BOSTON, USA – June 20, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the appointment of Mich...
CureVac
About the publication
19 June 2023 05:30PM
CureVac Announces Voting Results of General Meeting
NL0015436031
CureVac Announces Voting Results of General Meeting   TÜBINGEN, Germany / BOSTON, USA – June 19, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general m...
CureVac
About the publication
19 June 2023 05:30PM
CureVac Announces Voting Results of General Meeting
NL0015436031
CureVac Announces Voting Results of General Meeting   TÜBINGEN, Germany / BOSTON, USA – June 19, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's annual general m...
CureVac
About the publication
30 May 2023 01:00PM
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
NL0015436031
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update   Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Filed infringement counterclaim in U.S. patent litigation with Pfize...
CureVac
About the publication
30 May 2023 01:00PM
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
NL0015436031
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update   Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK Filed infringement counterclaim in U.S. patent litigation with Pfize...
CureVac
About the publication
19 May 2023 01:00PM
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
NL0015436031
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech   Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly ...
CureVac
About the publication
19 May 2023 01:00PM
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
NL0015436031
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech   Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly ...
CureVac
About the publication
08 May 2023 01:00PM
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
NL0015436031
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK   Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates Candidates developed in collaboration with GSK within broad infectious disease vaccine progr...
CureVac
About the publication
More CureVac related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN